RU2015105588A - Антитело, специфическое к cd22, и способы его применения - Google Patents

Антитело, специфическое к cd22, и способы его применения Download PDF

Info

Publication number
RU2015105588A
RU2015105588A RU2015105588A RU2015105588A RU2015105588A RU 2015105588 A RU2015105588 A RU 2015105588A RU 2015105588 A RU2015105588 A RU 2015105588A RU 2015105588 A RU2015105588 A RU 2015105588A RU 2015105588 A RU2015105588 A RU 2015105588A
Authority
RU
Russia
Prior art keywords
antibody
paragraphs
antibody according
amino acid
acid sequence
Prior art date
Application number
RU2015105588A
Other languages
English (en)
Russian (ru)
Inventor
Дэвид РАБУКА
Роберт Джордж Эдвард ХОЛГЕЙТ
Френсис Джозеф КАРР
Original Assignee
Редвуд Байосайнс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Редвуд Байосайнс, Инк. filed Critical Редвуд Байосайнс, Инк.
Publication of RU2015105588A publication Critical patent/RU2015105588A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/10—Peptides being immobilised on, or in, an organic carrier the carrier being a carbohydrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
RU2015105588A 2012-07-19 2013-07-15 Антитело, специфическое к cd22, и способы его применения RU2015105588A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261673630P 2012-07-19 2012-07-19
US61/673,630 2012-07-19
PCT/US2013/050489 WO2014014821A1 (en) 2012-07-19 2013-07-15 Antibody specific for cd22 and methods of use thereof

Publications (1)

Publication Number Publication Date
RU2015105588A true RU2015105588A (ru) 2016-09-10

Family

ID=49949191

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015105588A RU2015105588A (ru) 2012-07-19 2013-07-15 Антитело, специфическое к cd22, и способы его применения

Country Status (10)

Country Link
US (4) US9181343B2 (enExample)
EP (2) EP2874650A4 (enExample)
JP (2) JP6578206B2 (enExample)
KR (1) KR102165464B1 (enExample)
CN (1) CN104582717B (enExample)
AU (1) AU2013290424B2 (enExample)
CA (1) CA2878642C (enExample)
IN (1) IN2015DN00552A (enExample)
RU (1) RU2015105588A (enExample)
WO (1) WO2014014821A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6578206B2 (ja) * 2012-07-19 2019-09-18 レッドウッド バイオサイエンス， インコーポレイテッド Ｃｄ２２に特異的な抗体およびその使用方法
CA2935748A1 (en) 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
US11427647B2 (en) 2014-04-27 2022-08-30 Famewave Ltd. Polynucleotides encoding humanized antibodies against CEACAM1
MX366359B (es) * 2014-04-27 2019-07-05 Ccam Biotherapeutics Ltd Anticuerpos humanizados contra la molecula de adhesion celular relacionada al antigeno carcinoembrionico 1 (ceacam1).
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
ES2908470T3 (es) 2015-11-09 2022-04-29 Scherer Technologies Llc R P Conjugados de anticuerpo anti-CD22-maitansina y métodos de uso de los mismos
KR102808275B1 (ko) 2017-04-14 2025-05-20 탈락 테라퓨틱스, 인크. 면역조절 폴리뉴클레오티드, 이의 항체 접합체, 및 이의 사용 방법
TW201920249A (zh) * 2017-09-07 2019-06-01 美商信號生物製藥公司 具有結合位點之t細胞調節多聚體多肽及其使用方法
WO2021022166A1 (en) 2019-08-01 2021-02-04 R.P. Scherer Technologies, Llc Antibody specific for gpc3 and methods of use thereof
AU2021226336A1 (en) * 2020-02-27 2022-08-11 Phanes Therapeutics, Inc. Antibodies conjugated with fatty acid molecules and uses thereof
US11920136B2 (en) * 2020-02-28 2024-03-05 Tallac Therapeutics, Inc. Transglutaminase-mediated conjugation
JP2023527462A (ja) * 2020-06-01 2023-06-28 イノベイション バイオ カンパニー リミテッド Ｃｄ２２に特異的な抗体およびその使用
US20230372522A1 (en) * 2020-09-29 2023-11-23 Kunming Sinoway Natural Pharmaceuticals Co., Ltd. Humanized anti-cd22 recombinant immunotoxin and application thereof
KR20220122844A (ko) * 2021-02-26 2022-09-05 (주)이노베이션바이오 Cd22에 특이적인 인간화 항체 및 이의 용도
EP4419562A4 (en) * 2021-10-18 2025-10-08 Sinomab Bioscience Ltd AQUEOUS FORMULATIONS OF AN ANTI-CD22 ANTIBODY AND THEIR USES
WO2025059162A1 (en) 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4866132A (en) 1986-04-17 1989-09-12 The Research Foundation Of State University Of New York Novel radiopaque barium polymer complexes, compositions of matter and articles prepared therefrom
US5256334A (en) 1988-09-08 1993-10-26 The Research Foundation Of The State University Of New York Homogeneous radiopaque polymer-organobismuth composites
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
TW197439B (enExample) 1991-04-04 1993-01-01 Ueno Pharmaceutics Applic Res Co Ltd
WO1993003769A1 (en) 1991-08-20 1993-03-04 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES Adenovirus mediated transfer of genes to the gastrointestinal tract
US5283253A (en) 1991-09-23 1994-02-01 Florida State University Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them
US5621083A (en) 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
AU3140093A (en) 1991-11-22 1993-06-15 University Of Mississippi, The Synthesis and optical resolution of the taxol side chain and related compounds
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5200534A (en) 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
JPH08500973A (ja) 1992-05-21 1996-02-06 ザ ペン ステイト リサーチ ファウンデーション タキソール、関連タキサン及び他の新規な抗癌／抗ウイルス性化合物原料としてのイチイ培養組織
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
US5274137A (en) 1992-06-23 1993-12-28 Nicolaou K C Intermediates for preparation of taxols
US5294637A (en) 1992-07-01 1994-03-15 Bristol-Myers Squibb Company Fluoro taxols
US5202448A (en) 1992-08-14 1993-04-13 Napro Biotherapeutics, Inc. Processes of converting taxanes into baccatin III
CA2100808A1 (en) 1992-10-01 1994-04-02 Vittorio Farina Deoxy paclitaxels
FR2696463B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
FR2696458B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
FR2696464B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveau procédé d'estérification de la baccatine III et de la désacétyl-10 baccatine III.
FR2696462B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
FR2696461B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveaux dérivés d'analogues du taxol, leur préparation et les compositions qui les contiennent.
JPH08503855A (ja) 1992-12-03 1996-04-30 ジェンザイム・コーポレイション 嚢胞性線維症に対する遺伝子治療
US5279949A (en) 1992-12-07 1994-01-18 Board Of Trustees Operating Michigan State University Process for the isolation and purification of taxol and taxanes from Taxus spp
US5346981A (en) 1993-01-13 1994-09-13 Miles Inc. Radiopaque polyurethanes
US5484892A (en) 1993-05-21 1996-01-16 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
ATE304604T1 (de) 1993-06-24 2005-09-15 Frank L Graham Adenovirus vektoren für gentherapie
US5824701A (en) 1993-10-20 1998-10-20 Enzon, Inc. Taxane-based prodrugs
DE69434594T2 (de) 1993-10-25 2006-09-21 Canji, Inc., San Diego Rekombinante adenoviren-vektor und verfahren zur verwendung
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
AU3272695A (en) 1994-08-12 1996-03-07 Immunomedics Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US5625048A (en) 1994-11-10 1997-04-29 The Regents Of The University Of California Modified green fluorescent proteins
DE69526377T2 (de) 1994-12-09 2002-11-07 Microscience Ltd Virulenzgene in der VGC2-Region von Salmonella
US5939045A (en) 1994-12-22 1999-08-17 Nissan Chemical Industries, Ltd. Organic bismuth derivatives for X-ray imaging
US5958713A (en) 1995-01-31 1999-09-28 Novo Nordisk A/S Method of detecting biologically active substances by using green fluorescent protein
US5670477A (en) 1995-04-20 1997-09-23 Joseph F. Poduslo Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents
CN1113066C (zh) 1995-04-21 2003-07-02 帝国脏器制药株式会社 新型肽衍生物
ATE247488T1 (de) 1995-10-13 2003-09-15 Us Gov Health & Human Serv Immunotoxin enthaltend ein disulfid- stabilisiertes antikörperfragment
US5968738A (en) 1995-12-06 1999-10-19 The Board Of Trustees Of The Leland Stanford Junior University Two-reporter FACS analysis of mammalian cells using green fluorescent proteins
US6020192A (en) 1996-01-18 2000-02-01 University Of Florida Humanized green fluorescent protein genes and methods
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
ATE267610T1 (de) 1996-03-20 2004-06-15 Immunomedics Inc Glykosylierte igg antikörper
US5821263A (en) 1996-08-26 1998-10-13 Bristol-Myers Squibb Company Sulfenamide taxane derivatives
PT939647E (pt) 1996-08-27 2002-04-29 Chiron Corp Glicpconjugados do serogrupo b de neisseria meningitidis e metodos de utilizacao dos mesmos
AU739028B2 (en) 1996-09-27 2001-10-04 Bristol-Myers Squibb Company Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
TW371617B (en) 1996-10-09 1999-10-11 Of Animal And Plant Health Inspection And Quarantine Council Of Agriculture Executive Yuan Bureau Method to transplant GFP into autographa californica multiple nuclear polyhedrosis virus for inflicting pest in an attempt to detect and flow up it existence and to improve life span against UV
US6653104B2 (en) 1996-10-17 2003-11-25 Immunomedics, Inc. Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
WO1998022451A1 (en) 1996-11-19 1998-05-28 Daiichi Pharmaceutical Co., Ltd. Taxol derivatives
US5977386A (en) 1996-12-24 1999-11-02 Bristol-Myers Squibb Company 6-thio-substituted paclitaxels
DE69838979T2 (de) * 1997-03-20 2008-12-24 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren
US6183744B1 (en) 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
DE69831224T2 (de) 1997-05-02 2006-03-23 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immuntoxine, die ein onc protein enthalten, gegen bösartige zellen
SK182599A3 (en) 1997-06-20 2000-07-11 Baker Norton Pharma Soluble prodrugs of paclitaxel
GB9712892D0 (en) 1997-06-20 1997-08-20 Eclagen Ltd Identification of mhc binding peptides
US7288665B1 (en) 1997-08-18 2007-10-30 Florida State University Process for selective derivatization of taxanes
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
JPH1192468A (ja) 1997-09-17 1999-04-06 Yakult Honsha Co Ltd 新規なタキサン誘導体
JP4153660B2 (ja) 1997-10-08 2008-09-24 株式会社横浜国際バイオ研究所 タキソイド誘導体およびその製造方法
JP2001525470A (ja) 1997-12-12 2001-12-11 マクロメド・インコーポレーテッド タンパク修飾のためのヘテロ官能化星形ポリ（エチレングリコール）
US5985577A (en) 1998-10-14 1999-11-16 The Trustees Of Columbia University In The City Of New York Protein conjugates containing multimers of green fluorescent protein
EP1194167B1 (en) 1999-06-09 2009-08-19 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
PA8535501A1 (es) 2001-01-05 2003-07-28 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina
GB0105924D0 (en) 2001-03-09 2001-04-25 Microscience Ltd Promoter
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
CA2461351C (en) 2001-09-26 2014-08-05 Ira H. Pastan Mutated anti-cd22 antibodies with increased affinity to cd22-expressing leukemia cells
DE60334364D1 (de) * 2002-02-21 2010-11-11 Univ California Behandlungsverfahren unter verwendung von anti-cd22-antikörpern
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
EP1551453A4 (en) 2002-06-17 2007-04-25 Us Gov Health & Human Serv SPECIFICITY GRAFTING OF A MICE RESPONSE TO A HUMAN FRAME
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
CN102532321B (zh) 2004-06-18 2018-10-12 Ambrx公司 新颖抗原结合多肽和其用途
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
US7255012B2 (en) 2004-12-01 2007-08-14 Rosemount Inc. Process fluid flow device with variable orifice
EP2388271A3 (en) 2005-02-03 2012-08-01 Antitope Limited Human Antibodies and Proteins
EP2395026B1 (en) * 2005-02-08 2018-01-24 The Chemo-Sero-Therapeutic Research Institute Method for improving antibody
EP1998799B8 (en) 2006-03-06 2014-03-05 Medlmmune, LLC Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
WO2007140371A2 (en) * 2006-05-30 2007-12-06 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
US7985783B2 (en) * 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
EP2097097B1 (en) * 2006-12-01 2018-05-30 E. R. Squibb & Sons, L.L.C. Antibodies, in particular human antibodies, that bind cd22 and uses thereof
US9238878B2 (en) * 2009-02-17 2016-01-19 Redwood Bioscience, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
BR112012012873B1 (pt) * 2009-12-22 2021-08-31 F.Hoffmann-La Roche Ag Método para fornecer uma sequência de ácido nucleico que codifica uma imunoglobulina e método para produzir uma imunoglobulina
UY33679A (es) * 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
JP6578206B2 (ja) * 2012-07-19 2019-09-18 レッドウッド バイオサイエンス， インコーポレイテッド Ｃｄ２２に特異的な抗体およびその使用方法

Also Published As

Publication number Publication date
CA2878642A1 (en) 2014-01-23
JP6578206B2 (ja) 2019-09-18
EP2874650A1 (en) 2015-05-27
KR20150036700A (ko) 2015-04-07
WO2014014821A1 (en) 2014-01-23
JP2019150052A (ja) 2019-09-12
KR102165464B1 (ko) 2020-10-14
US12116409B2 (en) 2024-10-15
EP3539563A1 (en) 2019-09-18
CN104582717A (zh) 2015-04-29
AU2013290424B2 (en) 2018-01-25
US10259871B2 (en) 2019-04-16
CA2878642C (en) 2020-12-22
EP2874650A4 (en) 2016-03-23
IN2015DN00552A (enExample) 2015-06-26
US9181343B2 (en) 2015-11-10
JP2015530973A (ja) 2015-10-29
US20220220198A1 (en) 2022-07-14
AU2013290424A1 (en) 2015-02-05
CN104582717B (zh) 2018-03-13
US20160229911A1 (en) 2016-08-11
US20190352395A1 (en) 2019-11-21
US20140161870A1 (en) 2014-06-12

Similar Documents

Publication Publication Date Title
JP2015530973A5 (enExample)
JP7335290B2 (ja) 二重特異性四価抗体並びにその製作及び使用方法
JP6872181B2 (ja) ＩｇＧ結合ペプチドによる抗体の特異的修飾
JP2018520092A5 (enExample)
CN104582717B (zh) 对cd22有特异性的抗体及其使用方法
EA201391159A1 (ru) Hla-рестриктированные пептидоспецифические антигенсвязывающие белки
NZ750366A (en) Chimeric antigen receptors targeting bcma and methods of use thereof
HRP20220172T1 (hr) Protutijela protiv cd71 koja se mogu aktivirati, te postupci njihove uporabe
HRP20231118T1 (hr) Sintetizirani polipeptidi koji vežu transferinske receptore
HRP20200679T1 (hr) Molekule koje vežu antigen i sadrže trimer tnf ligand obitelji
SI2530091T1 (en) Anti-dll3 antibody
RU2018141360A (ru) Contorsbody - одноцепочечный связывающий мишень агент
CN107750169A (zh) 包含蒽环类衍生物的结合蛋白药物缀合物
HRP20231578T1 (hr) Molekule protutijela na april i njihove uporabe
HRP20200882T1 (hr) Vezujuće molekule specifične za asct2 i njihova uporaba
HRP20201091T1 (hr) Protutijela anti-axl
HRP20150934T1 (hr) Djelovanje na abcb5 u terapiji raka
Taylor et al. Nanocell targeting using engineered bispecific antibodies
JP2010534191A5 (enExample)
JP2019512207A5 (enExample)
KR20200092301A (ko) 다중-특이적 항체 및 이를 제조하는 방법 및 이의 용도
Tomé-Amat et al. Efficient in vivo antitumor effect of an immunotoxin based on ribotoxin α-sarcin in nude mice bearing human colorectal cancer xenografts
WO2017060322A3 (en) Ptefb-inhibitor-adc
ME02653B (me) Genski proizvodi koji su diferencijalno izraženi u tumorima i njihova primjena
RS63943B1 (sr) Humanizovana antitela protiv psma

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20160718